4D Molecular Therapeutics Inc
$ 9.45
0.53%
27 Apr - close price
- Market Cap 479,884,000 USD
- Current Price $ 9.45
- High / Low $ 9.77 / 9.27
- Stock P/E N/A
- Book Value 8.78
- EPS -2.42
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -0.28 %
- 52 Week High 12.34
- 52 Week Low 3.00
About
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in Emeryville, California.
Analyst Target Price
$28.78
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-27 | 2025-11-10 | 2025-08-11 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-09 | 2023-05-10 |
| Reported EPS | 0.43 | -1.01 | -0.98 | -0.86 | -0.9 | -0.79 | -0.63 | -0.66 | -0.75 | -0.24 | -0.77 | -0.88 |
| Estimated EPS | -0.532 | -1.01 | -0.73 | -0.8621 | -0.8379 | -0.7 | -0.7 | -0.74 | -0.74 | -0.59 | -0.81 | -0.89 |
| Surprise | 0.962 | 0 | -0.25 | 0.0021 | -0.0621 | -0.09 | 0.07 | 0.08 | -0.01 | 0.35 | 0.04 | 0.01 |
| Surprise Percentage | 180.8271% | 0% | -34.2466% | 0.2436% | -7.4114% | -12.8571% | 10% | 10.8108% | -1.3514% | 59.322% | 4.9383% | 1.1236% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.97 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FDMT
2026-04-26 20:10:29
The article discusses the collaboration between 4DMT and Otsuka to advance eye disease treatments in the Asia-Pacific (APAC) region. This partnership aims to bring new therapeutic options to patients suffering from various ophthalmic conditions in these markets.
2026-04-18 19:09:14
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on April 14, 2026, its compensation committee granted 67,600 Restricted Stock Units (RSUs) to five new non-executive employees. These grants were made under the Company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
2026-04-18 05:09:47
4D Molecular Therapeutics (4DMT) has announced employment inducement grants to new employees as required by Nasdaq rules. These grants were approved by the Compensation Committee of the company's Board of Directors and reported on April 15, 2026. The grants, including stock options and restricted stock units, are meant to attract and retain new talent.
2026-04-17 19:38:38
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 67,600 Restricted Stock Units (RSUs) to five new non-executive employees on April 14, 2026. These grants were made under the company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company developing therapeutics for diseases like wet age-related macular degeneration and cystic fibrosis.
2026-04-17 19:38:38
4D Molecular Therapeutics (Nasdaq: FDMT) announced that its compensation committee granted a total of 67,600 Restricted Stock Units (RSUs) to five new non-executive employees on April 14, 2026. These grants, made under the company's 2025 Employment Inducement Award Plan and Nasdaq Rule 5635(c)(4), are intended to attract new talent. This action aligns with the company's ongoing hiring and expansion efforts, particularly as it advances its late-stage gene therapy programs.
2026-04-17 16:05:00
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 67,600 Restricted Stock Units (RSUs) to five new non-executive employees on April 14, 2026. These grants were made under the Company’s 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
